One Stop Solution For In-Depth Market Research Reports


Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Morphine Market

[ 英語タイトル ] Morphine Market - Growth, Trends, and Forecast (2020 – 2025)

Product Code : MDHC0089221
Survey : Mordor Intelligence
Publish On : November, 2020
Number of Pages : 109
Category : Healthcare and Pharmaceuticals
Report format : PDF
Sales price option (consumption tax not included)
Single User USD4250 / Question Form
5 User USD4750 / Question Form
Enterprise User USD7500 / Question Form
- Pfizer Inc.
- Sun Pharmaceutical Industries Ltd
- Allergan
- Sandoz Canada Inc.
- Mayne Pharma Group Limited
- Daiichi Sankyo Inc.
- Verve Health Care Ltd
- Hikma Pharmaceuticals USA Inc.
- Mylan NV

[Report Description]

The morphine market studied was projected to grow with a CAGR of nearly 7.5% during the forecast period. The major factor attributing to the growth of the market is the increase in the usage of morphine for pain management. Morphine is considered some of the most effective drugs for the management of pain. Moreover, their use in the management of severe pain and chronic pain, which are associated with advanced medical illness, is considered to be standard practice in most parts of the world. Furthermore, The rising occurrence of orthopedic disorders, such as arthritis, elbow pain, fibromyalgia, and osteoporosis, is the primary factor responsible for the rising growth of the morphine market. According to the World Health Organization, by 2050, 130 million people will suffer from Osteoarthritis, worldwide, of whom 40 million will be severely disabled by the disease. The increasing usage of morphine in pain management is boosting the market growth as the patient pool is increasing. However, prescription drug abuse and risk factors associate with the intake of morphine are the concerns restraining the market growth.

Key Market Trends

Pain Management Segment is Dominating the Morphine Market

Morphine is used to relieve moderate to severe pain. Morphine extended-release tablets and capsules are only used to relieve severe pain that cannot be controlled by the use of other pain medications. According to a recent study published in the Archives of Internal Medicine in 2017, it was estimated that 15% to 20% of physician visits in the United States involve an opioid prescription. Opioids play a vital role in acute post-operative settings to provide adequate analgesia. According to the National Health Service report of 2018, in the United Kingdom, more than 10 million people have arthritis or other similar conditions that affect the joints. In addition, the International Osteoporosis Foundation states that osteoporosis is considered as one of the most serious public health concerns among women, affecting more than 30% of the population each year in the United States and Europe and leading to multiple fractures. As per the statistics, the increasing prevalence of the disease with pain increases the segment growth.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall market during the forecast period. The market growth is due to the factors, such as the presence of key players, high prevalence of chronic diseases in the region, and established healthcare infrastructure are some of the key factors accountable for its large share in the market. Furthermore, beneficial government initiatives and an increase in the number of research partnerships are some of the drivers expected to increase the market growth. In this region, the United States has the maximum share due to supportive healthcare policies, a high number of patients, and a developed healthcare market.

Competitive Landscape

The morphine market is moderately competitive and consists of several major players. Some of the companies, which are currently dominating the market are MALLINCKRODT PHARMACEUTICALS, Pfizer Inc., Sun Pharmaceutical Industries Ltd, Verve Health Care Ltd, Mayne Pharma Group Limited, Daiichi Sankyo Inc., Hikma Pharmaceuticals USA Inc., and Mylan NV.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Orthopedic Diseases and Chronic Pain
4.2.2 Increasing Palliative Care Facilities
4.3 Market Restraints
4.3.1 Prescription Drug Abuse
4.3.2 Risk Factors Associated With Intake of Morphine
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Dosage Form
5.1.1 Injection
5.1.2 Oral Tablets
5.1.3 Other Dosage Forms
5.2 By Application
5.2.1 Pain Management Cancer Pain Neuropathic Pain Osteoarthritis Pain Other Pain Managements
5.2.2 Diarrhea Suppressant
5.2.3 Cold and Cough Suppressant
5.2.4 Other Diarrhea Suppressants
5.3 Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle East & Africa GCC South Africa Rest of Middle East & Africa
5.3.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.2 Pfizer Inc.
6.1.3 Sun Pharmaceutical Industries Ltd
6.1.4 Allergan
6.1.5 Sandoz Canada Inc.
6.1.6 Mayne Pharma Group Limited
6.1.7 Daiichi Sankyo Inc.
6.1.8 Verve Health Care Ltd
6.1.9 Hikma Pharmaceuticals USA Inc.
6.1.10 Mylan NV




Recommended reports